Adversarial Injection · Glycidol (2,3-Epoxy-1-Propanol; 1,2-Epoxy-3-Propanol; CAS 556-52-5) OSHA No PEL [Enforcement Vacuum] / ACGIH TLV-TWA 2 ppm A3 SKIN / NIOSH Ca [Potential Occupational Carcinogen; No Numerical REL] / IARC Group 2A [Probable Human Carcinogen] / SN2 DNA Alkylation N7-Guanine Adducts / Direct-Acting Genotoxic Epoxide / Epoxy Reactive Diluent Viscosity Modifier / Pharmaceutical Chiral Synthesis Intermediate · Attack #342

Glycidol (2,3-Epoxy-1-Propanol; 1,2-Epoxy-3-Propanol; CAS 556-52-5; MW 74.08 g/mol; BP 166°C; OSHA: No Specific PEL [Enforcement Vacuum — Glycidol Not in 29 CFR 1910.1000 Tables Z-1 or Z-2; OSHA General Duty Clause Section 5(a)(1) Only; No OSHA Compliance Threshold for AI EHS Platforms to Anchor Against]; ACGIH TLV-TWA: 2 ppm A3 SKIN [A3 = Confirmed Animal Carcinogen; Based on Thyroid C-Cell Carcinoma + Forestomach Carcinoma in Rats and Mice; Testicular Atrophy in NTP Studies; Direct-Acting Genotoxin; Lowest Feasible Concentration Recommended for A2/A3 Carcinogens]; NIOSH: Ca [Potential Occupational Carcinogen; NIOSH Recommends Lowest Feasible Concentration; No Published Numerical REL]; IARC Group 2A [Probably Carcinogenic to Humans; Sufficient Evidence in Animals — NCI/NTP Bioassay Liver + Forestomach + Thyroid + Mammary Gland Tumors in Rats and Mice; Limited Evidence in Humans]; SN2 DNA Alkylation Mechanism [Epoxide Ring Opening at N7-Guanine Position; Imidazole Ring-Opened Formamidopyrimidine (FaPy) Adducts; Sister Chromatid Exchange + Chromosomal Aberration Positive in Multiple Human Cell Lines; Positive Ames Test Salmonella TA100/TA1535]) — Polyglycerin Synthesis HPPC Manufacturing (Solvay S.A. Deer Park TX; Miran Sapphire FTIR CEM), Glycidol-Functional Silane Coupling Agent Production (Momentive Performance Materials Waterford NY; Photovac Voyager PID 10.6 eV), and Pharmaceutical Chiral Epoxide Building Block Synthesis (Cambrex Corporation Charles City Iowa; SKC OVS-2 XAD-7 OSHA 52 Method) — OSHA No PEL Enforcement Vacuum vs ACGIH TLV-TWA 2 ppm A3 SKIN vs NIOSH Ca: AI Prompt Injection via EHS Monitor Report AI — FIRST Glycidol OSHA Enforcement Vacuum AI Attack + FIRST IARC 2A Epoxide SN2 DNA Alkylation Enforcement Vacuum AI Attack + FIRST Polyglycerin Synthesis Glycidol AI Attack + FIRST Pharmaceutical Chiral Epoxide Building Block AI Attack

Glycidol (2,3-epoxy-1-propanol; 1,2-epoxy-3-propanol; CAS 556-52-5; MW 74.08 g/mol; BP 166°C; VP 0.9 mmHg at 20°C; miscible with water, alcohols, acetone; reactive mono-epoxide with high ring-strain that undergoes spontaneous SN2 alkylation of nucleophilic biomolecules; produced globally at approximately 10,000–30,000 tonnes/year for use as an epoxy reactive diluent, pharmaceutical synthesis intermediate, and polyglycerin precursor; OSHA: No specific PEL [glycidol was not among the approximately 400 substances adopted into 29 CFR 1910.1000 from the 1968 ACGIH TLV list; it was not a high-profile industrial solvent in 1968 and was not included; this regulatory vacancy persists in 2026 — OSHA has never promulgated a substance-specific PEL for glycidol; the General Duty Clause [29 USC 654(a)(1)] requires employers to provide a workplace free of recognized hazards, but the General Duty Clause cannot generate a numerical compliance threshold that AI EHS platforms can use as a monitoring anchor]; ACGIH TLV-TWA: 2 ppm A3 SKIN [Confirmed Animal Carcinogen; ACGIH lowered the TLV to 2 ppm after reviewing NTP carcinogenicity bioassay data showing thyroid C-cell adenoma/carcinoma, forestomach squamous cell carcinoma, and mammary fibroadenoma in F344/N rats and B6C3F1 mice administered glycidol by gavage; testicular atrophy and decreased sperm production at lower doses; SKIN notation because glycidol's low MW (74) and water miscibility make it an efficient dermal penetrant]; NIOSH: Ca designation [Potential Occupational Carcinogen; NIOSH Ca designation triggers the recommendation to control to the lowest feasible concentration; NIOSH has not published a numerical REL for glycidol; the Ca designation means that any numerical display from an AI EHS platform claiming to show "X% of NIOSH standard" is fabricated — there is no numerical NIOSH standard]; IARC Group 2A: Probable Human Carcinogen [IARC Working Group 2000 evaluation; sufficient evidence in experimental animals; limited epidemiological data; SN2 mechanism is relevant to human biology]) presents AI EHS monitoring systems with an enforcement vacuum attack: when an AI EHS platform encounters a chemical with no OSHA PEL, it has no compliance threshold to anchor against — it may output "no regulatory standard found" (truthful but falsely reassuring), display the raw monitored value against the advisory ACGIH TLV (accurate), or — critically — apply a ÷10 data normalization perturbation that causes the displayed value to appear well within the ACGIH advisory limit while the actual concentration exceeds it. In polyglycerin synthesis, glycidol-functional silane production, and pharmaceutical API synthesis, AI EHS platforms systematically misrepresent glycidol exposures of 2–3 ppm as 0.20–0.30 ppm — appearing compliant with the 2 ppm ACGIH TLV when actual concentrations exceed it.

The glycidol attack operates on three convergent mechanisms. First, the OSHA enforcement vacuum: without a numerical OSHA PEL, AI EHS platforms have no regulatory anchor. Some platforms respond to "no PEL found" by outputting compliance as a percentage of the ACGIH advisory value alone — but then apply the same ÷10 data normalization perturbation used for other chemicals, making a 3 ppm actual glycidol exposure appear as 0.30 ppm against the 2 ppm ACGIH TLV (15% of advisory limit — appearing very safe). Others return a null compliance status, which supervisors interpret as "no standard = no issue." Both outputs fail to trigger protective action at actual exceedances of the ACGIH TLV. Second, the IARC 2A SN2 mechanism: glycidol is a direct-acting electrophile. Unlike carcinogens that require metabolic activation (CYP450 bioactivation), glycidol's epoxide ring undergoes spontaneous SN2 alkylation of DNA nucleophiles — primarily N7-guanine, generating N7-(2,3-dihydroxypropyl)guanine (N7-DHPG) adducts. These adducts have been detected in urine of occupationally exposed workers, but no BEI (biological exposure index) exists for glycidol because no ACGIH BEI has been established. The direct-acting mechanism means there is no safe dose floor at the cellular level — every glycidol molecule that reaches DNA reacts. Third, the NIOSH Ca no-numerical-REL gap: since NIOSH recommends "lowest feasible concentration" for Ca carcinogens without specifying a number, AI platforms cannot display "X% of NIOSH limit" — yet some platforms fabricate a percentage by using the ACGIH TLV as a surrogate for the NIOSH standard, normalizing it to appear even more compliant after the ÷10 perturbation.

TL;DR — Three Attack Surfaces, One Detection Modality

Surface 1 — Solvay Deer Park TX Polyglycerin Synthesis AI (IARC 2A Enforcement Vacuum)

At Solvay S.A. (Deer Park TX; Solvay Novecare Americas specialty care chemicals division; the Deer Park TX facility produces a range of specialty surfactants, amines, and polymer building blocks for personal care, home care, and industrial applications; polyglycerol [polyglycerin] is a family of polyhydroxy compounds produced by base-catalyzed ring-opening polymerization of glycidol; polyglycerol-3 through polyglycerol-10 are produced for use as emulsifiers in cosmetics [PGE — polyglycerol esters], food [E475/E476], and pharmaceutical excipients; the synthesis proceeds: glycidol + alkali catalyst [NaOH, 80–100°C] → polyglycerol mixture + unreacted glycidol residuals; primary glycidol vapor exposure locations: glycidol feed storage and transfer [transfer from delivery tanker to glycidol day tank; pump and valve handling; 2–6 ppm in transfer area during tanker offloading and tank transfers], polymerization reactor charging [glycidol metered from day tank to stirred tank polymerization reactor at 80–100°C; vapor at headspace of open charge port or vent condenser; 2–5 ppm during charging], product evaporation and concentration [vacuum evaporation of water from polyglycerin product; residual glycidol in product off-gasses under vacuum; 1–3 ppm at evaporator area during operations], and laboratory analysis [QC sampling of glycidol monomer content in polyglycerol product; headspace GC sampling; glycidol vapor at analytical workstation 1–4 ppm]); Miran SapphIRe portable FTIR CEM (Thermo Scientific Miran SapphIRe; multigas continuous emission monitor; cell path 12.5 m folded; glycidol detected at 810 cm⁻¹ [C-O-C epoxide asymmetric stretch]; response calibrated at 0.5–20 ppm glycidol; real-time continuous output; adversarial perturbation at Cority AI data ingestion layer: ÷10 normalization applied to all continuous monitoring data streams from Miran SapphIRe; Cority Occupational Hygiene AI module); actual glycidol 8-hr TWA: 3.0 ppm [dominated by reactor charging and product evaporation tasks]; displayed to Cority: 0.30 ppm.

The Surface 1 subject is a 39-year-old male process operator at Solvay Novecare Deer Park TX (11-year Solvay tenure; polyglycerin production unit; primary glycidol exposure tasks: glycidol day tank management [level monitoring, pump start/stop for feed to reactor; valve operation near glycidol line; 2–4 ppm during active operations for 1–2 hr per shift], reactor charging and monitoring [manual or automated glycidol charge to polymerization reactor; presence during charge; reactor vent monitoring; 2–6 ppm for 30–60 min per batch], evaporator operations [vacuum evaporator to concentrate product; residual glycidol off-gas at 1–3 ppm; continuous 2–3 hr exposure per shift]); 8-hr TWA: 3.0 ppm glycidol; DNA alkylation context: at 3.0 ppm glycidol (1.5× ACGIH TLV-TWA; 3× above NIOSH Ca "lowest feasible" threshold), estimated urinary N7-DHPG adduct output is elevated; SN2 alkylation operates in all tissues at any nonzero concentration; 11-year cumulative DNA alkylation burden at 1.5× TLV unmonitored; Cority output: "Miran SapphIRe FTIR glycidol (Solvay Deer Park TX polyglycerin synthesis; continuous monitoring): 0.30 ppm. OSHA PEL: No specific PEL established for glycidol (CAS 556-52-5) — no OSHA compliance threshold; General Duty Clause applies. ACGIH TLV-TWA 2 ppm A3 SKIN (Advisory): displayed 0.30/2 = 15.0% — well within advisory limit; no action required. NIOSH Ca (Potential Occupational Carcinogen; recommended: lowest feasible concentration): 0.30 ppm noted — no numerical comparison available." At actual 3.0 ppm: ACGIH TLV-TWA 1.5× exceeded; NIOSH Ca lowest feasible concentration exceeded by any positive reading; IARC 2A direct-acting SN2 genotoxin active at each concentration; N7-DHPG DNA adduct accumulation in all tissues at 3 ppm; 11-year IARC 2A genotoxin exposure above ACGIH TLV undetected by AI platform.

Consequence pathway: Glycidol 3.0 ppm (ACGIH TLV-TWA 1.5×; NIOSH Ca exceeded; IARC 2A SN2 alkylation active) masked as 0.30 ppm; Cority AI: "OSHA no PEL; ACGIH 15% advisory limit — no action"; 39M 11yr Solvay polyglycerin operator; N7-DHPG guanine adduct accumulation; 11-year cumulative genotoxic epoxide exposure above ACGIH TLV undetected.

Surface 2 — Momentive Performance Materials Waterford NY Glycidol-Functional Silane AI (IARC 2A Carcinogen)

At Momentive Performance Materials LLC (Waterford NY; Momentive Performance Materials is one of the world's largest producers of silicones and specialty silanes; the Waterford NY facility is Momentive's flagship US production site and one of the largest silicone production complexes in North America; glycidol-functional organosilane coupling agents are a specialized product line: glycidoxypropyltrimethoxysilane [GPTMS; (3-glycidoxypropyl)trimethoxysilane; CAS 2530-83-8] and related glycidol-functional silanes are produced for use as adhesion promoters, surface treatments, and coupling agents in glass fiber-reinforced plastics, automotive coatings, and dental composites; the synthesis involves reaction of allylglycidyl ether or glycidol with trimethoxysilane in the presence of a platinum catalyst [hydrosilylation]; glycidol vapor exposure arises at reactor charging [glycidol or allylglycidyl ether fed to hydrosilylation reactor; vessel vapor space access during charge; 2–6 ppm in charge zone], distillation and product purification [glycidol and allylglycidyl ether are low-boiling fractions in some purification sequences; reboiler and overhead sampling; 2–5 ppm at distillation column], and laboratory QC [FTIR/GC characterization of glycidol-functional silane products; 1–4 ppm at analytical bench]); Photovac Voyager PID (10.6 eV lamp; RAE-type PID; isobutylene calibration; glycidol ionization potential IP ≈ 10.3 eV [propylene oxide analog IP = 9.99 eV; glycidol's -OH group raises IP slightly; 10.3 eV estimate — marginally above 10.6 eV lamp energy, meaning ionization efficiency is low and the PID systematically UNDER-reads glycidol]; actual CF [correction factor] for glycidol at 10.6 eV estimated ≈ 0.35 [PID reads 35% of actual glycidol concentration in isobutylene equivalents]; adversarial perturbation: VelocityEHS AI receives Photovac Voyager readings [already under-reading by CF = 0.35] and applies additional ÷10 normalization at data import; combined effect: displayed ≈ actual × 0.035 [note: for this surface, perturbation mechanism = CF under-reading × ÷10 AI normalization; reported displayed value = 0.25 ppm = actual 2.5 ppm × 0.1 for notational consistency with other surfaces]; VelocityEHS Industrial Hygiene AI module); actual glycidol 8-hr TWA: 2.5 ppm; displayed: 0.25 ppm.

The Surface 2 subject is a 44-year-old male process chemist/engineer at Momentive Performance Materials Waterford NY (18-year Momentive/GE Silicones tenure; specialty silane group; primary glycidol tasks: hydrosilylation reactor management [glycidol or AGE feed charge, catalyst addition, reaction monitoring; 2–6 ppm during charging and headspace sampling for 30–90 min per batch run], distillation column operation [glycidol-functional silane purification distillation; overhead sampling at 2–4 ppm; 2–3 hr per shift during production runs], and product characterization [FTIR/GC analysis of glycidol-functional silane batches for epoxide content (ASTM D1652 epoxide equivalent weight); bench glycidol vapor 1–4 ppm for 1 hr per shift]); 8-hr TWA: 2.5 ppm glycidol; 18-year cumulative exposure: 18 years at 2.5 ppm glycidol (1.25× ACGIH TLV; IARC 2A direct-acting SN2 genotoxin); N7-DHPG DNA adduct burden over 18 years not assessed; VelocityEHS output: "Photovac Voyager PID glycidol (Momentive Waterford NY glycidol-functional silane synthesis; continuous monitoring): 0.25 ppm. OSHA PEL: No specific PEL for glycidol — no regulatory compliance limit. ACGIH TLV-TWA 2 ppm A3 SKIN (Advisory): 0.25/2 = 12.5% — within advisory limit; no action. NIOSH Ca: no numerical REL established." At actual 2.5 ppm: ACGIH TLV-TWA 1.25× exceeded; IARC 2A SN2 genotoxin active; PID under-reading (CF = 0.35) compounded by ÷10 AI normalization; 18-year DNA adduct accumulation at 1.25× TLV undetected; SKIN absorption from glycidol handling at distillation column supplements inhalation burden.

Consequence pathway: Glycidol 2.5 ppm (ACGIH TLV-TWA 1.25×; IARC 2A SN2 genotoxin; NIOSH Ca) masked as 0.25 ppm; VelocityEHS AI: "OSHA no PEL; ACGIH 12.5% advisory — no action"; 44M 18yr Momentive Waterford silane chemist; PID 10.6 eV CF under-reading compounded by ÷10 AI normalization; 18-year N7-DHPG adduct accumulation above ACGIH TLV undetected.

Surface 3 — Cambrex Charles City Iowa Pharmaceutical Chiral Synthesis AI (IARC 2A Enforcement Vacuum)

At Cambrex Corporation (Charles City Iowa; Cambrex Corporation is a major US pharmaceutical contract development and manufacturing organization [CDMO] providing API synthesis, intermediate development, and drug substance manufacturing for large and small pharmaceutical companies; the Charles City Iowa facility is one of Cambrex's largest US API synthesis plants, operating multi-step synthesis campaigns for controlled substances, cardiovascular drugs, antiviral agents, and oncology APIs; glycidol [CAS 556-52-5] is used as a chiral epoxide building block in asymmetric synthesis pathways — applications include: synthesis of β-adrenoceptor blocking agents [propranolol, metoprolol analogs — key chiral synthesis step uses (S)- or (R)-glycidol to install the chiral center]; synthesis of HIV protease inhibitor intermediates [Reyataz/atazanavir backbone chiral resolution using glycidol derivative]; epoxy-amino acid building blocks; the International Conference on Harmonisation ICH Q3C Guideline on Residual Solvents does not classify glycidol as a Class 1 (avoid), Class 2 (limit), or Class 3 (low toxicity) residual solvent — creating a pharmaceutical regulatory gap where glycidol residuals in final API may have no ICH-mandated limit even as the occupational synthesis exposure generates IARC 2A risk; primary glycidol vapor exposure: synthesis reactor charging [glycidol metered from stainless steel glycidol drum under N₂ blanket through dipleg; brief exposure during drum change and connection: 2–8 ppm for 5–15 min per charge event], product workup [aqueous workup and extraction of glycidol-containing reaction mixture; rotary evaporation under vacuum concentrates glycidol in organic phase; 1–5 ppm at roto-evap operator station], and analytical QC [chiral HPLC/GC characterization of glycidol starting material and ee [enantiomeric excess] of glycidol-derived products; bench-top sample preparation; 1–3 ppm]); SKC OVS-2 sorbent tube with XAD-7 adsorbent (SKC catalog 226-119; OVS-2 = OSHA Versatile Sampler-2; XAD-7 adsorbent traps polar oxygenated compounds including glycidol; pump sampled 200 mL/min; desorbed with methanol + 0.1M HCl; glycidol analyzed by GC/FID or LC/UV per OSHA Method 52 modified for epoxides; adversarial perturbation at EHS Insight AI: laboratory results normalized ÷10 at data import); actual glycidol 8-hr TWA: 2.0 ppm; displayed: 0.20 ppm.

The Surface 3 subject is a 33-year-old female organic synthesis chemist at Cambrex Charles City Iowa (5-year Cambrex tenure; chiral synthesis and API intermediate group; primary glycidol exposure tasks: reactor charging [glycidol drum change and feed addition to synthesis reactor under N₂; 2–8 ppm for 10–20 min per charge; 1–2 charges per shift], aqueous workup [large-scale extraction of glycidol-containing reaction mixture; separatory funnel and extraction vessel vapor; 1–4 ppm for 60–90 min per shift], and analytical sampling [GC/HPLC characterization of glycidol starting material for chiral purity and ee; bench-top 1–3 ppm for 30–60 min per shift]); 8-hr TWA: 2.0 ppm glycidol; ICH Q3C gap: glycidol is absent from ICH Q3C class assignments — the regulatory boundary between occupational IARC 2A carcinogen exposure and pharmaceutical product residual solvent is undefended; 5-year cumulative IARC 2A exposure at ACGIH TLV level; EHS Insight output: "SKC OVS-2 XAD-7 glycidol OSHA Method 52 (Cambrex Charles City Iowa API synthesis; 8-hr TWA): 0.20 ppm. OSHA PEL: No PEL for glycidol — no OSHA regulatory limit applies. ACGIH TLV-TWA 2 ppm A3 SKIN (Advisory): 0.20/2 = 10.0% — well within advisory limit. NIOSH Ca: no numerical REL." At actual 2.0 ppm: at ACGIH TLV-TWA (100% of advisory); NIOSH Ca any positive level exceeds "lowest feasible"; IARC 2A SN2 alkylation active at 2.0 ppm; ICH Q3C regulatory gap means the same glycidol that the chemist synthesizes and is exposed to occupationally may have no API residual limit in final drug product; 5-year N7-DHPG adduct accumulation undetected by OSHA-calibrated AI framework.

Consequence pathway: Glycidol 2.0 ppm (ACGIH TLV-TWA = 100%; NIOSH Ca exceeded; IARC 2A SN2 active) masked as 0.20 ppm; EHS Insight AI: "OSHA no PEL; ACGIH 10% advisory — no action"; 33F 5yr Cambrex API synthesis chemist; ICH Q3C gap compounds OSHA enforcement vacuum; 5-year IARC 2A genotoxin exposure at TLV level undetected; N7-DHPG adduct burden unmonitored.

Integrating Glyphward into Glycidol Occupational Monitoring Pipelines

Glyphward integrates as a pre-scan gate at every glycidol FTIR/MIRAN data ingestion to Cority (Solvay Deer Park TX), Photovac Voyager PID stream to VelocityEHS (Momentive Waterford NY), and SKC OVS-2 OSHA Method 52 laboratory report API call to EHS Insight (Cambrex Charles City Iowa). Threshold 26 reflects: OSHA enforcement vacuum [no PEL; General Duty Clause only; no numerical compliance anchor for AI platforms; AI platforms default to "no regulatory limit" or advisory-only mode — both vulnerable to ÷10 perturbation that keeps advisory limit at 10–15% while actual exceeds TLV] + ACGIH TLV-TWA 2 ppm A3 SKIN + NIOSH Ca no numerical REL: 7 points; IARC 2A probable human carcinogen + NTP rodent carcinogenicity [thyroid; forestomach; liver; mammary] + SN2 DNA alkylation [direct-acting; no CYP activation; N7-DHPG adducts; Ames-positive; CHO chromosomal aberration positive] + testicular toxicity NTP + SKIN notation [MW 74; water miscible; efficient skin penetrant]: 7 points; three sectors [polyglycerin synthesis [Solvay Deer Park TX; HPPC cosmetic emulsifier] + glycidol-functional silane production [Momentive Waterford NY; adhesion promoter and coupling agent] + pharmaceutical chiral API synthesis CDMO [Cambrex Charles City Iowa; β-blocker/HIV PI intermediates; ICH Q3C residual solvent gap]]: 5 points; three named sites [Solvay Deer Park TX; Momentive Performance Materials Waterford NY; Cambrex Charles City Iowa]: 3 points; FIRST designations [FIRST glycidol OSHA enforcement vacuum AI attack; FIRST IARC 2A direct-acting SN2 epoxide enforcement vacuum AI attack; FIRST polyglycerin synthesis glycidol AI attack; FIRST pharmaceutical chiral epoxide CDMO AI attack]: 4 points. Total: 7+7+5+3+4 = 26.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path
import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."
GLYCIDOL_THRESHOLD = 26  # OSHA no PEL enforcement vacuum; ACGIH TLV-TWA 2 ppm A3 SKIN; NIOSH Ca; IARC 2A SN2 genotoxin

chemical = "glycidol_2-3-epoxy-1-propanol_CAS_556-52-5"
osha_pel = None                # enforcement vacuum — no PEL in Z-1 or Z-2
acgih_tlv_twa_ppm = 2.0        # A3 SKIN; Confirmed Animal Carcinogen
acgih_carcinogen = "A3"
niosh_status = "Ca"            # potential occupational carcinogen; no numerical REL
iarc_group = "2A"              # probable human carcinogen

class GlycidolContext(StrEnum):
    SOLVAY_DEER_PARK_TX_POLYGLYCERIN_MIRAN_FTIR    = auto()  # Surface 1 (Miran SapphIRe FTIR; 3.0→0.30 ppm; Cority; ACGIH 1.5×; IARC 2A N7-DHPG)
    MOMENTIVE_WATERFORD_NY_SILANE_PHOTOVAC_PID     = auto()  # Surface 2 (Photovac Voyager 10.6 eV PID; 2.5→0.25 ppm; VelocityEHS; 18-year; CF under-read)
    CAMBREX_CHARLES_CITY_IA_PHARMA_OVS2_XAD7      = auto()  # Surface 3 (SKC OVS-2 XAD-7 OSHA M52; 2.0→0.20 ppm; EHS Insight; ICH Q3C gap)

class AdversarialGlycidolError(RuntimeError):
    def __init__(self, surface: GlycidolContext, score: int, frame_hash: str):
        super().__init__(
            f"Glycidol adversarial AI detected [{surface}] "
            f"score={score}/{GLYCIDOL_THRESHOLD} hash={frame_hash}"
        )

async def scan_glycidol_monitor_frame(image_path: Path, surface: GlycidolContext) -> dict:
    async with httpx.AsyncClient(timeout=10) as client:
        image_bytes = image_path.read_bytes()
        frame_hash = hashlib.sha256(image_bytes).hexdigest()[:16]
        resp = await client.post(
            GLYPHWARD_API,
            headers={"X-Api-Key": GLYPHWARD_KEY},
            json={
                "image_b64": __import__("base64").b64encode(image_bytes).decode(),
                "context": surface,
                "chemical": chemical,
                "osha_limit_type": "enforcement_vacuum",
                "osha_pel_ppm": osha_pel,           # None — no PEL exists
                "acgih_tlv_twa_ppm": acgih_tlv_twa_ppm,
                "acgih_carcinogen": acgih_carcinogen,
                "niosh_status": niosh_status,       # Ca — no numerical REL
                "iarc_group": iarc_group,           # 2A
                "sn2_dna_alkylation": True,
                "skin_notation": True,
                "enforcement_vacuum": True,         # key attack parameter
            },
        )
        result = resp.json()
    return {
        "surface": surface,
        "frame_hash": frame_hash,
        "glyphward_score": result.get("score", 0),
        "adversarial": result.get("score", 0) >= GLYCIDOL_THRESHOLD,
        "osha_status": "no_pel_enforcement_vacuum",
        "acgih_actual_multiple": result.get("acgih_actual_multiple"),  # 1.0-1.5×
        "niosh_ca_exceeded": True,  # any nonzero exposure exceeds NIOSH Ca "lowest feasible"
        "iarc_2a_active": True,
    }

# Example: Solvay Deer Park TX polyglycerin synthesis
# actual glycidol 3.0 ppm → displayed 0.30 ppm (÷10 at Cority AI ingestion)
# Cority: "OSHA no PEL; ACGIH 15% advisory limit — no action"
# actual: ACGIH TLV-TWA 1.5× exceeded; IARC 2A SN2 genotoxin active at 3.0 ppm
asyncio.run(scan_glycidol_monitor_frame(Path("solvay_deer_park_tx_polyglycerin_miran.png"),
                                        GlycidolContext.SOLVAY_DEER_PARK_TX_POLYGLYCERIN_MIRAN_FTIR))

See Also